Annovis Bio (ANVS) Stock Is About to $100: Should You Book Profit?

Investors looking into the major gainers will find it hard to miss the Annovis Bio (NYSEAMERICAN:ANVS) stock, which has soared by 248% to $92.03 after the company announced positive results with regards to its Alzheimer’s and Parkinson’s treatment.

Annovis Bio (ANVS) Stock Is About to $100: Should You Book Profit?

The company announced that the treatment improved the cognitive abilities of the patients in less than a month. Annovis administered its treatment to 28 patients and then compiled a study on its efficacy. Half of the patients in the study suffered from Parkinson’s disease and the other half were afflicted with Alzheimer’s disease.

Related:  Biolase (BIOL) Doubles This Year: How To Trade After Earnings?

After the patients had been treated for a period of 25 days, the ones who had been treated with the Annovis product demonstrated improvement on a key measure as opposed to those who were treated with Placebo. More importantly, the results showed that the treatment performed better than the similar treatment from Cassava Sciences and Biogen. It is a significant development for Annovis and the market seems to think so as well.

Anthony Gonzales

Biotech, Tech, and Crypto reporter Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.